Melatonin and its receptors: A new class of sleep-promoting agents

Journal of Clinical Sleep Medicine

Volumn 3, Issue 5 SUPPL., 2007, Pages

  Doghramji, Karl ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; HORMONE RECEPTOR STIMULATING AGENT; LY 156735; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; RAMELTEON; UNCLASSIFIED DRUG; VEC 162;

CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HOMEOSTASIS; HUMAN; META ANALYSIS; NAUSEA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34548482007     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.26932     Document Type: Review

References (75)

1. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002;3:591-605.
2. Vitaterna MH, Takahashi JS, Turek FW. Overview of circadian rhythms. Alcohol Res Health 2001;25:85-93.
3. Turek FW, Dugovic C, Zee PC. Current understanding of the circadian clock and the clinical implications for neurological disorders. Arch Neurol 2001;58:1781-7.
4. Richardson GS. The human circadian system in normal and disordered sleep. J Clin Psychiatry 2005;66 Suppl 9:3-9.
5. Piggins HD. Human clock genes. Ann Med 2002;34:394-400.
6. Hamet P, Tremblay J. Genetics of the sleep-wake cycle and its disorders. Metabolism 2006;55 Suppl 2:S7-S12.
7. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001;24:726-31.
8. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 1993;13:1065-79.
9. Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci 2002;5 Suppl: 1071-5.
10. Cassone VM. Effects of melatonin on vertebrate circadian systems. Trends Neurosci 1990;13:457-64.
11. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003;17:273-85.
12. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95.
13. Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science 1975;187:169-71.
14. Waldhauser F, Dietzel M. Daily and annual rhythms in human melatonin secretion: role in puberty control. Ann N Y Acad Sci 1985;453:205-14.
15. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-92.
16. Brown GM. Light, melatonin and the sleep-wake cycle. J Psychiatry Neurosci 1994;19:345-53.
17. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004;5:523-32.
18. Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 1997;12:627-35.
19. Krauchi K, Wirz-Justice A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology 2001;25:S92-6.
20. Stone BM, Turner C, Mills SL, Nicholson AN. Hypnotic activity of melatonin. Sleep 2000;23:663-9.
21. Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995;57:552-8.
22. Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 1997;12:657-65.
23. Lavie P. Sleep-wake as a biological rhythm. Annu Rev Psychol 2001;52:277-303.
24. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-85.
25. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8.
26. Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275:31311-7.
27. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003;8:d1093-108.
28. Morgan PJ. The pars tuberalis: the missing link in the photoperiodic regulation of prolactin secretion? J Neuroendocrinol 2000;12:287-95.
29. Pintor J, Martin L, Pelaez T, Hoyle CH, Peral A. Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 2001;416:251-4.
30. Lotufo CM, Lopes C, Dubocovich ML, Farsky SH, Markus RP. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 2001;430:351-7.
31. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102.
32. Jin X, von Gall C, Pieschl RL, et al. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 2003;23:1054-60.
33. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. Faseb J 1998;12:1211-20.
34. Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 1982;54:1025-7.
35. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307-13.
36. Melatonin. Med Lett Drugs Ther 1995;37:111-2.
37. Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment No. 108. (Prepared by the University of Alberta Evidence-based Practice Center, under Contract No. 290-02-0023). AHRQ Publication No. 05-E002-2. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
38. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-8.
39. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50.
40. Karasek M, Reiter RJ, Cardinali DP, Pawlikowski M. Future of melatonin as a therapeutic agent. Neuro Endocrinol Lett 2002;23 Suppl 1:118-21.
41. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10.
42. Hibberd M, Stevenson SJ. A phase-I open-label study of the absorption, metabolism, and exretion of (14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects (abstract). Sleep 2004;27(suppl):A54.
43. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006;46:140-8.
44. Stevenson S, Cornelissen K, Clarke E, Hibberd M. Study of the ab-sorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) (abstract). Clin Pharmacol Ther 2004;75:22.
45. Amakye DD, Hibberd M, Stevenson SJ. A phase I study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects (abstract). Sleep 2004;27(suppl):A54.
46. Stevenson S, Bryson S, Amakye D, Hibberd M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects (abstract). Clin Pharmacol Ther 2004;75:22.
47. Rozerem™ [package insert], Takeda Pharmaceuticals America, Inc., Lincolnshire, Illinois (August 2005).
48. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders D-IV-TR. Washington, DC: American Psychiatric Association; 2004.
49. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24.
50. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;In press.
51. Mini L, Wang-Weigand S, Zhang J, Kasten K. Reduction in sleep latency during 5 weeks of treatment with ramelteon 8 mg versus placebo in patients with chronic insomnia. Neurology 2006;66(suppl 2):A9.
52. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-8.
53. Richardson G, Wang-Weigand S, Zhang J, DeMicco M. Long-term safety of ramelteon treatment in adults with chronic insomnia. Sleep 2006;29(suppl):A233.
54. Sleep Disorder (Sedative-Hypnotic) Drug Information. FDA Press Release P07-45, March 14, 2007. Accessed at http://www.fda.gov/ bbs/topics/NEWS/2007/ NEW01587.html on April 30, 2007.
55. Richardson GS, Wang-Weigand S, Sainati S, Demissie S. Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study. Clin Pharmacol Ther 2006;79:P68.
56. Sainati S, Tsymbalov S, Demissie S, Roth T. Double-blind, placebo-controlled, two-way crossover study of ramelteon in subjects with mild to moderate chronic obstructive pulmonary disease (COPD). Sleep 2005;28(suppl):A162.
57. Sainati S, Tsymbalov S, Demissie S, Roth T. Double-blind, single-dose, two-way crossover of ramelteon in subjects with mild to moderate obstructive sleep apnea. Sleep 2005;28(suppl):A163.
58. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-57.
59. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992;35:1484-6.
60. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64.
61. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47.
62. Van Reeth O, Olivares E, Turek FW, Granjon L, Mocaer E. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 1998;9:1901-5.
63. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 1995;118:385-90.
64. Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000;880:207-11.
65. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993;46:45-9.
66. Ying SW, Rusak B, Delagrange P, Mocaer E, Renard P, Guardiola-Lemaitre B. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996;296:33-42.
67. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272: R1178-88.
68. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005;63:298-304.
69. Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder (abstract). Eur Neuropsychopharmacol 2005;15 (Suppl 3):S419.
70. Quera-Salva MA, Vanier B, Chapotot F, Bohic M, Andre S, Moulin C. Effects of agomelatine on the sleep EEG in patients with major depressive disorder (abstract). Eur Neuropsychopharmacol 2005;15 (Suppl. 3):435-6.
71. Nickelsen T, Samel A, Vejvoda M, Wenzel J, Smith B, Gerzer R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 2002;19:915-36.
72. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-90.
73. Zemlan F, Mulchahey J, Mayleben D, Scharf M, Rosenberg R, Lankford A. Multicenter study of the melatonin agonist LY 156735 in moderate-to-severe primary insomnia. In: Program No 3106 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005. Online, 2005.
74. Rajaratnam SM, Polymeropoulos MH, Fischer DM, Scott CH, Birznieks G, Klerman EB. The melatonin agonist VEC-162 immeidately phase-advances the human circadian system (abstract). In: 20th Anniversary Meeting of the Associated Professional Sleep Societies; 2005; Salt Lake City, UT; 2005.
75. Kilduff TS, Kushida CA. Circadian regulation of sleep. In: Chokroverty S, ed. Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects 2nd ed. Boston, MA: Butterworth-Henieman, 1999:135-45.